The Cardiovascular Effects of Nitrogen Dioxide Exposure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00774514 |
Recruitment Status :
Completed
First Posted : October 17, 2008
Last Update Posted : April 9, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Endothelial Dysfunction | Procedure: Forearm Vascular Study | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 12 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | The Cardiovascular Effects of Nitrogen Dioxide Exposure |
Study Start Date : | October 2008 |
Actual Primary Completion Date : | December 2008 |
Actual Study Completion Date : | December 2008 |
Arm | Intervention/treatment |
---|---|
Experimental: Air exposure
1 hour exposure to filtered air during intermittent exercise
|
Procedure: Forearm Vascular Study
Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
Other Names:
|
Experimental: NO2 exposure
1 hour exposure to nitrogen dioxide at 4ppm during intermittent exercise
|
Procedure: Forearm Vascular Study
Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
Other Names:
|
- Forearm blood flow measured by venous occlusion plethysmography in response to intraarterial vasodilators (acetylcholine, sodium nitroprusside, bradykinin and verapamil) [ Time Frame: 4-6 hours after exposure ]
- Plasma t-PA concentrations after infusion of bradykinin [ Time Frame: During forearm study ]
- Exhaled nitric oxide [ Time Frame: 4-6 hours after exposure ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy male volunteers
Exclusion Criteria:
- Current smokers
- Significant occupational exposure to air pollution
- Regular medication use
- Intercurrent illness

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00774514
Sweden | |
Umeå University | |
Umeå, Sweden |
Principal Investigator: | Thomas Sandström, MD PhD | Umeå University | |
Principal Investigator: | Anders Blomberg, MD PhD | Umeå University |
Responsible Party: | Dr Anders Blomberg, Umeå University |
ClinicalTrials.gov Identifier: | NCT00774514 |
Other Study ID Numbers: |
Dnr 08-113M |
First Posted: | October 17, 2008 Key Record Dates |
Last Update Posted: | April 9, 2009 |
Last Verified: | April 2009 |
Air Pollution Nitrogen Dioxide NO2 Endothelial dysfunction |